The firm said total revenues fell to $424.0 million from $461.4 million in the first quarter of 2019, below analysts' consensus estimate of $444.4 million.
The firm delayed reporting final results due to questions of accounting irregularities but found no misconduct and made no changes to its preliminary results.
Bruker has postponed reporting of its final Q4 and full-year 2019 results, but reported preliminary Q4 revenues of $599.9 million and full-year revenues of $2.07 billion.
Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.
With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.
The firm completed financing actions raising around $1.2 billion in funds that it plans to use to provide financial flexibility and fund corporate objectives.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
